Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724288 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL29546840 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL29493294 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL15467376 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL2255636 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL17724339 | 0.89 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL26317865 | 0.89 | NPC1 (0.37) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL28606425 | 0.89 | NPC1 (0.37) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL21932895 | 0.88 | ALOX15 (0.35) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL20076133 | 0.88 | ALOX15 (0.35) | ALOX15KDM4ENPC1RAB9APTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | ALOX15 3075/4885KDM4E 3259/4885NPC1 3838/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | ALOX15 1992/4885KDM4E 3943/4885NPC1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.